Oncology Research Therapeutics is dedicated to providing and discovering breakthrough cancer diagnostics that will dramatically improve the lives of patients suffering from a wide array of cancers. We also provide R&D services that will improve drug development for the Biotech and Pharmaceutical industries. ORT Inc. provides clinical laboratory services that improve currently available chemotherapy cancer treatment options available to the physician and patient, and also enable the pharmaceutical industry to more rapidly and cost-effectively develop new cancer treatment drugs. Your physician can directly order ORT laboratory tests if he or she has determined that the Chemoresistance/Sensitivity Assay or other ORT cancer testing services are right for you.
Veridex, LLC, a Johnson & Johnson company, is an organization dedicated to providing physicians and patients with high-value in vitro diagnostic oncology products.Veridex's products will significantly benefit patients through earlier disease detection, and will enable personalized medicine strategies to improve patient management and outcomes. The company develops cancer diagnostic products that will enable earlier disease detection as well as more accurate staging, monitoring and therapeutic selection. The company is initially developing two product lines: CellSearchâ„¢ assays that enumerate circulating tumor cells in blood and GeneSearchâ„¢ assays using molecular technology.
Zymed Laboratories, Inc. is an integrated, technology-driven, immunoassay reagent company based in South San Francisco, CA. Zymed serves 2 primary segments: life sciences research and clinical diagnostics. Our product portfolio reflects Zymed's strategy of being a value-added, total-systems solution developer, manufacturer, and worldwide marketer of advanced reagents and reagent systems for life science research, clinical research, and cancer diagnostics. Zymed's research reagents are pathway-driven, focusing on cell signaling pathways with well characterized primary antibodies, novel tissue arrays, and protein arrays. Our goal is to aid biotechnology, pharmaceutical, and research scientists in their discovery and development efforts, including high throughput screening programs. Zymed's routine diagnostics business targets pathology labs with a comprehensive line of slide-based cellular and molecular reagent systems, including antibody tumor markers, DNA probes, detection systems, and complete assay kits for both manual and automated staining using biopsy specimens. Zymed has over 21 years of technological expertise in antibody design, development, modification, purification, and production. Zymed is ISO 13485 certified by TUV Rheinland of North America, Inc.
http://www.medical-solutions.co.uk
Medical Solutions is a leading provider of expert, quality services and products to the healthcare, pharma biotech and life science research sectors. Medical Solutions has an unparallelled combination of expertise in diagnostic pathology, cytology and genomics. This places Medical Solutions in a unique position to fully exploit the increasing demand for outsourced support services and specialist diagnostic capabilities. The group has its headquarters in Nottingham, UK where it operates state of the art reference laboratory facilities, but also operates laboratories in Cambridge and Oxford.
We are dedicated to present options and deliver solutions that work. We take the time to research and identify the needs of each client to ensure delivery of innovative promotional media. CX Designs was created out of the increasing need for small businesses and non-profit organizations, like yours, to create a strong marketing presence. We deliver effective marketing solutions for local and international clients of all types. Regardless of location, we can work with you. Many of our clients are spread throughout the United States, Canada and France, offering you an international marketing flair at economical prices. Flash, custom photography... we can add any bell or whistle to make your job turn heads, with fantastic results, every time. We have talented graphic artists and web designers who can put together a look that is just right for your organization. Whether you need a full business package, web site, one poster or business cards, we will take care of it for you. We believe that your success is our success. Whether you are looking for print or electronic media, CX Designs has the solution for you.
Agendia has developed high-quality diagnostic methods using microarray gene expression profiling to determine the tumor's specific properties: MammaPrint® can reliably predict whether an individual breast cancer patient is at high or low risk of disease recurrence. In addition, Agendia also offers services aimed at identifying the primary (original) tumor in patients diagnosed with distant metastasis (tumors that have spread from the original source to distant organs or lymph nodes). Agendia's innovative and robust methods provide physicians and patients with crucial information for determining the optimal treatment plan based on personalized gene expression information. Gene expression profiling is an important new tool in diagnosis, prognosis, and the identification of novel drug targets. Agendia strives to offer state of the art DNA microarray technology and analytical approaches to physicians and pharmaceutical companies, improving the accuracy of metastasis risk prediction, disease origin, targeted drug development or pre-selection of patients eligible for clinical trials. It is Agendia's mission to provide cancer patients attainable access to the latest findings in gene-based diagnostics and thus improve the patient's quality of life by enabling effective personalized medicine.
http://www.exagendiagnostics.com
Exagen's unique technology enables us to queue up multiple, high-quality products for our licensing partners within two to three years. For more information about Exagen's capabilities in this area, please contact: Public Relations at Exagen Diagnostics, Inc. PublicRelations@Exagen.com
Perceptronix Medical Inc. is a privately owned, cancer diagnostics company based in Vancouver, Canada. The company was founded in 1999 to commercialize innovative cancer diagnosis technologies developed in partnership with the BC Cancer Agency, a renowned cancer research and treatment facility with a successful track record in implementing early cancer detection programs. We believe early diagnosis is the key to improving outcomes for cancer patients. Perceptronix's mission is to commercialize effective, clinically-relevant technologies for the earlier diagnosis of cancer. The company's initial focus is on a complementary portfolio of diagnostic products to improve lung cancer outcomes. Perceptronix has developed proprietary and novel methods that link into the diagnostic chain: detection, localization, diagnosis, treatment, and follow-up. (1) Licensed for sale in Canada & EU; (2) Licensed for sale in Canada, EU & USA; (3) In development, license not yet issued. Perceptronix holds an ISO 13485 quality certificate and is ISO 9001:2000 certified.
IMPATH Inc. (Nasdaq: IMPH) is in the business of improving outcomes for cancer patients. The Company is the leading source of cancer information and analyses with a database of more than 800,000 analyzed cases to date. IMPATH uses sophisticated technologies to provide patient-specific cancer diagnostic and prognostic information to pathologists, oncologists and transplant centers. IMPATH currently serves more than 7,850 physicians specializing in the treatment of cancer patients, in over 1,975 hospitals and 445 oncology practices. Utilizing its comprehensive resources, the IMPATH Predictive Oncology division serves genomics, biotechnology and pharmaceutical companies involved in developing new therapeutics targeted to specific, biological characteristics of cancer. IMPATH Cancer Registry(TM) is a trademark of IMPATH Inc.
Oncotech, Inc., based in Tustin, California, is an innovative oncology company, which provides state of the art molecular oncology laboratory services to assist physicians in the care and management of their cancer patients. To date, Oncotech Clinical Laboratory Division has performed oncology services for approximately 80,000 cancer patients from over 1,000 hospitals throughout the nation and Europe. Oncotech's mission is to improve the cancer patient's chances for survival and their quality of life. Oncotech recognizes that each patient's cancer is genetically unique and then works to discover, develop and introduce new products that assist cancer physicians in treating each cancer patient on a unique and individual basis.
Genomic Health, Inc. (Genomic Health) is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. The Company’s first test, Oncotype DX, is used for early stage breast cancer patients to predict the likelihood of cancer recurrence, the likelihood of patient survival within 10 years of diagnosis and the likelihood of chemotherapy benefit. It offers Oncotype DX as a clinical laboratory service. Oncotype DX has been evaluated in multiple independent studies involving more than 3,300 breast cancer patients. As of December 31, 2007, more than 46,500 tests had been delivered for use in treatment planning by more than 7,000 physicians. (Source: 10-K)
DakoCytomation produces a wide array of biochemical products used by health care professionals and researchers around the world for diagnostic and research purposes. The nature of our products and business areas may be difficult to assess without a specific scientific background, and it is our hope that this section may provide answers to questions raised by non-scientists. In describing the design and functionality of a certain product, technique, or application, it is impossible to avoid the use of scientific terms. However, we do hope you will find the information provided in this section useful. Please follow the links on the left to learn more about what we do.
DiagnoCure Inc. (DiagnoCure) is a biotechnology company commercializing cancer diagnostic tests and delivering lab services. The Company specializes in the development of cancer diagnostic assays incorporating molecular markers. As of October 31, 2007, DiagnoCure had three wholly owned subsidiaries, 9161-6722 Quebec Inc., 9184-6766 Quebec Inc. and Catalyst Oncology, Inc., which are involved in its ongoing business activities. On August 16, 2007, the Company acquired Catalyst oncology, Inc. of Worcester, Massachusetts, and its prognostic tests for breast, colon and other cancers. On November 1, 2007, DiagnoCure created DiagnoCure U.S., GP, a general partnership with 9184-6766 Quebec Inc., to conduct service laboratory activities in the United States. On November 3, 2006, the Company announced the closing of SAMBA technologies SAS. (Source: ARS)
Xenomics, Inc. is the developer of next-generation molecular diagnostics products that address important health problems worldwide. Our mission is to apply our proprietary transrenal DNA test platform to develop highly sensitive, truly non-invasive molecular diagnostics that replace outdated blood, sputum, and tissue testing technologies many of which are not sufficiently sensitive and specific, and are often hazardous, and difficult to automate. The patented technology uses simple urine specimens and can be applied to a broad range of products addressing multi-billion dollar markets including infectious disease detection and monitoring, cancer detection and monitoring, prenatal genetic testing, monitoring organ/cell transplants, human forensics, and biodefense. Xenomics has made continuing progress in its clinical studies in infectious disease testing, particularly in the field of TB detection and therapeutic monitoring, HIV proviral DNA detection, and detection of early cancer genetic markers.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory